JNJ63576253

CAS No. 2110428-64-1

JNJ63576253( TRC-253 )

Catalog No. M23962 CAS No. 2110428-64-1

JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 35 In Stock
5MG 58 In Stock
10MG 102 In Stock
25MG 222 In Stock
50MG 356 In Stock
100MG 530 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    JNJ63576253
  • Note
    Research use only, not for human use.
  • Brief Description
    JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
  • Description
    JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
  • In Vitro
    ——
  • In Vivo
    Animal Model:Castrated SHO mice with prostate LNCaP SRα F877L tumor Dosage:30 mg/kg Administration:P.o. once daily for 72 days Result:Inhibited the tumor growth by 87%.Animal Model:CD-1 male mice Dosage:2 mg/kg for i.v.; 10 mg/kg for p.o. (Pharmacokinetic Analysis)Administration:Intravenous administration and oral administration Result:I.v.: T1/2=5.99 h; CL=15.0 mL/min/kg; Vdss=6.11 L/kg.P.o.: F=45%; Cmax=0.66 μM; AUClast=4.9 μg?h/mL.
  • Synonyms
    TRC-253
  • Pathway
    Endocrinology/Hormones
  • Target
    Androgen Receptor (AR)
  • Recptor
    Androgen Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2110428-64-1
  • Formula Weight
    538.97
  • Molecular Formula
    C23H22ClF3N6O2S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 200mg/mL?(371.08 mM);H2O: insoluble
  • SMILES
    N#CC1=NC=C(N(C2=O)C(N(C3=CC=C(OC4CCNCC4)N=C3)C52CCC5)=S)C=C1C(F)(F)F.[H]Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Zhang Z , Connolly P J , Lim H K , et al. Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)[J]. Journal of Medicinal Chemistry, 2021, 64(2).
molnova catalog
related products
  • LY305

    LY305 (LY-305) is a non-steroidal selective androgen receptor modulator (SARM) with Ki of 2.03 nM.

  • BMS-986365

    BMS-986365 (CC-94676) is an orally available, selective and highly potent AR degrader with potential anticancer activity that inhibits AR signaling and suppresses tumor growth for the study of prostate cancer.

  • Adrenosterone

    Adrenosterone is a steroid hormone with weak androgenic effect.